Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure

Schreiber, 2003, Congestive heart failure in patients with chronic kidney disease and on dialysis, Am J Med Sci, 352, 179, 10.1097/00000441-200304000-00004 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040 Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 1999, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 Packer, 2002, Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study, Circulation, 106, 2194, 10.1161/01.CIR.0000035653.72855.BF Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 McKelvie, 1999, Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study, Circulation, 100, 1032, 10.1161/01.CIR.100.10.1056 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1 Keefe, 2000, Clinical pharmacology of telmisartan, J Clin Pharmacol, 40, 1311, 10.1177/009127000004001201 Marcelli, 2001, EuCliD (European Clinical Database): a database comparing different realities, J Nephrol, 14, S94 McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3 Cice, 2003, Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial, J Am Coll Cardiol, 41, 1438, 10.1016/S0735-1097(03)00241-9 Steil, 2004, EuCliD—a medical registry, Methods Inf Med, 43, 83, 10.1055/s-0038-1633841 Conte, 2004, Italian Registry of Dialysis and Transplantation: 1996–2001 experience, G Ital Nefrol, 21, 561 Robson, 1997, Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis, J Nephrol, 10, 33 2005, K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients, Am J Kidney Dis, 45, S1 Cice, 2001, Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial, J Am Coll Cardiol, 37, 407, 10.1016/S0735-1097(00)01158-X Takahashi, 2006, Candesartan, an angiotensin II tipe-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study, Nephrol Dial Transplant, 21, 2507, 10.1093/ndt/gfl293 Suzuki, 2008, Effect of angiotensin receptor blocker on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial, Am J Kidney Dis, 52, 501, 10.1053/j.ajkd.2008.04.031 Young, 2004, Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials, Circulation, 110, 2618, 10.1161/01.CIR.0000146819.43235.A9 Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: A randomized trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Health Failure Survival Study ELITE II, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3 Zannad, 2006, Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies, Kidney Int, 70, 1318, 10.1038/sj.ki.5001657 Brenner BM. Brenner and Rector's The Kidney. 8th edition. Philadelphia, PA: Saunders Book Company. Kelly, 1988, Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis, Br J Clin Pharmacol, 26, 781, 10.1111/j.1365-2125.1988.tb05319.x Metra, 2003, Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance, Am Heart J, 145, 292, 10.1067/mhj.2003.105 Tentori, 2007, Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?, J Am Soc Nephrol, 18, 2377, 10.1681/ASN.2006111250